Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Pulmonary Arterial Hypertension Treatment Pipeline Review H2 2016

Monday, October 17, 2016 3:56
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Pulmonary Arterial Hypertension – Pipeline Review, H2 2016’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @


- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
- The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pulmonary Arterial Hypertension Overview 9
Therapeutics Development 10
Pipeline Products for Pulmonary Arterial Hypertension – Overview 10
Pipeline Products for Pulmonary Arterial Hypertension – Comparative Analysis 11
Pulmonary Arterial Hypertension – Therapeutics under Development by Companies 12
Pulmonary Arterial Hypertension – Therapeutics under Investigation by Universities/Institutes 15
Pulmonary Arterial Hypertension – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pulmonary Arterial Hypertension – Products under Development by Companies 19
Pulmonary Arterial Hypertension – Products under Investigation by Universities/Institutes 23
Pulmonary Arterial Hypertension – Companies Involved in Therapeutics Development 24
Actelion Ltd 24
APT Therapeutics, Inc. 25
Arena Pharmaceuticals, Inc. 26
Ascendis Pharma A/S 27
AVEO Pharmaceuticals, Inc. 28
Bial – Portela & Ca, S.A. 29
Celsion Corporation 30
Celtaxsys, Inc. 31
Chugai Pharmaceutical Co., Ltd. 32
Complexa, Inc. 33
Eli Lilly and Company 34
Galectin Therapeutics, Inc. 35
Gilead Sciences, Inc. 36
Hanmi Pharmaceuticals, Co. Ltd. 37
HitGen LTD 38
Insmed Incorporated 39
INVENT Pharmaceuticals, Inc. 40
Johnson & Johnson 41
Kowa Company, Ltd. 42
Mast Therapeutics, Inc. 43
Mezzion Pharma Co. Ltd. 44
miRagen Therapeutics, Inc. 45
Morphogen-IX Limited 46
Nippon Kayaku Co., Ltd. 47
Nippon Shinyaku Co., Ltd. 48
Novartis AG 49
Peloton Therapeutics, Inc. 50
PhaseBio Pharmaceuticals, Inc. 51
Pluristem Therapeutics Inc. 52
Proteo, Inc. 53
Pulmokine, Inc. 54
Reata Pharmaceuticals, Inc. 55
Respira Therapeutics, Inc. 56
Reviva Pharmaceuticals Inc. 57
Selten Pharma, Inc 58
Silence Therapeutics Plc 59
SteadyMed Therapeutics, Inc. 60
Suda Ltd 61
Toray Industries, Inc. 62
Pulmonary Arterial Hypertension – Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Target 64
Assessment by Mechanism of Action 68
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
acebilustat – Drug Profile 76
Antibody for Pulmonary Arterial Hypertension – Drug Profile 79
Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension – Drug Profile 80
APT-602 – Drug Profile 81
AV-353 – Drug Profile 82
bardoxolone methyl – Drug Profile 83
beraprost sodium ER – Drug Profile 87
beraprost sodium SR – Drug Profile 88
BIA-51058 – Drug Profile 89
BMP-10 – Drug Profile 90
BMP-9 – Drug Profile 91
CTX-3397 – Drug Profile 92
CXA-10 – Drug Profile 93
Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension – Drug Profile 95
GMA-301 – Drug Profile 96
GMCT-01 – Drug Profile 97
GRMD-02 – Drug Profile 101
HGP-1207 – Drug Profile 112
INS-1009 – Drug Profile 113
INV-240 – Drug Profile 115
JNJ-26993135 – Drug Profile 116
KAR-5585 – Drug Profile 117
macitentan – Drug Profile 118
MFC-1040 – Drug Profile 123
MFC-2040 – Drug Profile 124
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases – Drug Profile 125
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension – Drug Profile 126
PB-1046 – Drug Profile 127
PB-1120 – Drug Profile 129
PF-543 – Drug Profile 130
pitavastatin NP – Drug Profile 131
PK-10453 – Drug Profile 132
PK-10571 – Drug Profile 133
PLX-PAD – Drug Profile 134
PT-2977 – Drug Profile 142
QCC-374 – Drug Profile 143
R-190 – Drug Profile 144
ralinepag – Drug Profile 146
RP-5063 – Drug Profile 148
RT-234 – Drug Profile 150
selexipag – Drug Profile 151
selonsertib – Drug Profile 155
sirolimus albumin-bound – Drug Profile 156
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology – Drug Profile 158
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension – Drug Profile 159
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension – Drug Profile 160
Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension – Drug Profile 161
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension – Drug Profile 162
sodium nitrite – Drug Profile 163
SPI-054 – Drug Profile 166
SPI-183 – Drug Profile 167
SUD-004 – Drug Profile 168
Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension – Drug Profile 169
tacrolimus – Drug Profile 170
tadalafil – Drug Profile 171
tiprelestat – Drug Profile 173
tocilizumab – Drug Profile 177
TR-422 – Drug Profile 185
treprostinil – Drug Profile 186
treprostinil diolamine – Drug Profile 187
ubenimex – Drug Profile 189
udenafil – Drug Profile 191
Pulmonary Arterial Hypertension – Dormant Projects 194
Pulmonary Arterial Hypertension – Discontinued Products 198
Pulmonary Arterial Hypertension – Product Development Milestones 199
Featured News & Press Releases 199
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 209
Disclaimer 210

Buy this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.